Business Context and Reporting Period
Spero Therapeutics, Inc. filed this Form 8-K on July 9, 2018. The report discloses preliminary financial data as of June 30, 2018, and announces the commencement of an underwritten public offering of common stock.
Key Financial Metrics
- Liquidity: Estimated cash, cash equivalents, and marketable securities were approximately $66.6 million as of June 30, 2018.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, or cash flow for the period.
- Debt and Margins: The filing text does not provide specific values for debt levels or operating margins.
Material Changes and Events
The primary material event reported is the initiation of an underwritten public offering of 4,500,000 shares of common stock (par value $0.001 per share) on July 9, 2018. The liquidity figure of $66.6 million is preliminary and subject to change upon the completion of the financial statements for the quarter ended June 30, 2018.
Guidance, Outlook, and Risks
Management noted that the preliminary financial data is unaudited and has not been reviewed by PricewaterhouseCoopers LLP. There is no assurance that the estimated cash position will not differ materially from the final audited figures. Complete quarterly results are expected to be included in the Form 10-Q for the quarter ended June 30, 2018. The filing does not contain specific forward-looking guidance or risk factors beyond the standard disclaimer regarding preliminary data.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-Q for the quarter ended June 30, 2018.
- Confirm the final terms and net proceeds of the 4,500,000 share public offering.
- Review the full quarterly results for revenue, net loss, and cash burn rate once the Form 10-Q is filed.